New Late Breaking Preliminary Data Demonstrate Balt’s Squid™ Liquid Embolic May Improve Outcomes in Patients with Chronic Subdural Hematomas
February 09, 2024 14:30 ET
|
Balt Group
BOSTON, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Balt, Inc., a global technology leader in neurovascular devices, today announced the presentation of preliminary data from The Squid Trial for the...
Balt Appoints Jeffrey Sachs Chief Legal & Compliance Officer
December 09, 2021 07:00 ET
|
Balt Group
BOSTON, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Balt, an innovative neurovascular company focused on developing, designing, and manufacturing solutions for treating complex, life-threatening conditions,...
Balt Completes Enrollment in FIRST: A Multi-center, Prospective, International Study of Low Profile Silk Vista Flow Diverters
July 28, 2021 07:00 ET
|
Balt Group
BOSTON, July 28, 2021 (GLOBE NEWSWIRE) -- Balt, an innovative neurovascular company focused on developing, designing, and manufacturing solutions for treating complex, life-threatening conditions,...